PMID- 37648188
OWN - NLM
STAT- Publisher
LR  - 20231022
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Linking)
VI  - 237
IP  - Pt 2
DP  - 2023 Nov 15
TI  - The molecular perspective on the melanoma and genome engineering of T-cells in 
      targeting therapy.
PG  - 116980
LID - S0013-9351(23)01784-X [pii]
LID - 10.1016/j.envres.2023.116980 [doi]
AB  - Melanoma, an aggressive malignant tumor originating from melanocytes in humans, 
      is on the rise globally, with limited non-surgical treatment options available. 
      Recent advances in understanding the molecular and cellular mechanisms underlying 
      immune escape, tumorigenesis, drug resistance, and cancer metastasis have paved 
      the way for innovative therapeutic strategies. Combination therapy targeting 
      multiple pathways simultaneously has been shown to be promising in treating 
      melanoma, eliciting favorable responses in most melanoma patients. CAR T-cells, 
      engineered to overcome the limitations of human leukocyte antigen (HLA)-dependent 
      tumor cell detection associated with T-cell receptors, offer an alternative 
      approach. By genetically modifying apheresis-collected allogeneic or autologous 
      T-cells to express chimeric antigen receptors, CAR T-cells can appreciate 
      antigens on cell surfaces independently of major histocompatibility complex 
      (MHC), providing a significant cancer cell detection advantage. However, 
      identifying the most effective target antigen is the initial step, as it helps 
      mitigate the risk of toxicity due to "on-target, off-tumor" and establishes a 
      targeted therapeutic strategy. Furthermore, evaluating signaling pathways and 
      critical molecules involved in melanoma pathogenesis remains insufficient. This 
      study emphasizes the novel approaches of CAR T-cell immunoediting and presents 
      new insights into the molecular signaling pathways associated with melanoma.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Hajibabaie, Fatemeh
AU  - Hajibabaie F
AD  - Department of Biology, Shahrekord Branch, Islamic Azad University, Shahrekord, 
      Iran; Department of Medical Biotechnology, Isfahan (Khorasgan) Branch, Islamic 
      Azad University, Isfahan, Iran. Electronic address: 
      fateme.hajibabaii1991@gmail.com.
FAU - Abedpoor, Navid
AU  - Abedpoor N
AD  - Department of Sports Physiology, Faculty of Sports Sciences, Isfahan (Khorasgan) 
      Branch, Islamic Azad University, Isfahan, Iran; Department of Medical 
      Biotechnology, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, 
      Iran. Electronic address: abedpoor.navid@yahoo.com.
FAU - Haghjooy Javanmard, Shaghayegh
AU  - Haghjooy Javanmard S
AD  - Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan 
      University of Medical Sciences, Isfahan, Iran. Electronic address: 
      shaghayegh.haghjoo@gmail.com.
FAU - Hasan, Anwarul
AU  - Hasan A
AD  - Department of Mechanical and Industrial Engineering, Qatar University, Doha, 
      2713, Qatar; Biomedical Research Center, Qatar University, Doha, 2713, Qatar. 
      Electronic address: hasan.anwarul.mit@gmail.com.
FAU - Sharifi, Mehran
AU  - Sharifi M
AD  - Department of Internal Medicine, School of Medicine, Cancer Prevention Research 
      Center, Seyyed Al-Shohada Hospital, Isfahan University of Medical Sciences, 
      Isfahan, Iran. Electronic address: m_sharifi.86374@yahoo.com.
FAU - Rahimmanesh, Ilnaz
AU  - Rahimmanesh I
AD  - Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan 
      University of Medical Sciences, Isfahan, Iran. Electronic address: 
      Ilnazrahimmanesh@gmail.com.
FAU - Shariati, Laleh
AU  - Shariati L
AD  - Department of Biomaterials, Nanotechnology and Tissue Engineering, School of 
      Advanced Technologies in Medicine, Isfahan University of Medical Sciences, 
      Isfahan, 8174673461, Iran; Biosensor Research Center, Isfahan University of 
      Medical Sciences, Isfahan, Iran. Electronic address: l.shariati@amt.mui.ac.ir.
FAU - Makvandi, Pooyan
AU  - Makvandi P
AD  - The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's 
      Hospital, Quzhou, 324000, Zhejiang, China; School of Engineering, Institute for 
      Bioengineering, The University of Edinburgh, Edinburgh, EH9 3JL, UK. Electronic 
      address: pooyanmakvandi@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230828
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
SB  - IM
OTO - NOTNLM
OT  - CAR T-cell
OT  - Immunotherapy
OT  - Melanoma
OT  - Molecular signaling pathway
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/08/31 00:41
MHDA- 2023/08/31 00:41
CRDT- 2023/08/30 19:25
PHST- 2023/07/08 00:00 [received]
PHST- 2023/08/19 00:00 [revised]
PHST- 2023/08/23 00:00 [accepted]
PHST- 2023/08/31 00:41 [pubmed]
PHST- 2023/08/31 00:41 [medline]
PHST- 2023/08/30 19:25 [entrez]
AID - S0013-9351(23)01784-X [pii]
AID - 10.1016/j.envres.2023.116980 [doi]
PST - ppublish
SO  - Environ Res. 2023 Nov 15;237(Pt 2):116980. doi: 10.1016/j.envres.2023.116980. 
      Epub 2023 Aug 28.